AD109

DRUG5 trials

Sponsors

Apnimed

Conditions

OSAOSA - Obstructive Sleep ApneaObstructive Sleep Apnea

Phase 2

Crossover Trial of AD109 in Obstructive Sleep Apnea

CompletedNCT04580394

ApnimedObstructive Sleep Apnea

Start: 2020-10-27End: 2021-05-28Updated: 2023-01-31

Parallel Arm Trial of AD109 and AD504 In Patients With OSA

CompletedNCT05071612

ApnimedOSA - Obstructive Sleep Apnea

Start: 2021-11-29End: 2022-08-03Updated: 2026-08-12

Study That Tests AD109 in Patients Taking GLP-1 Drugs

CompletedNCT06400615

Start: 2024-05-20End: 2024-12-26Updated: 2025-02-19

Phase 3

Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)

CompletedNCT05811247

Start: 2023-08-28End: 2025-05-07Updated: 2025-11-21

Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)

CompletedNCT05813275

Start: 2023-09-16End: 2025-03-14Updated: 2026-09-11

Related Papers

Aroxybutynin and atomoxetine (AD109) for obstructive sleep apnea: a randomized phase 3 trial (SynAIRgy).

2026-05-18

Aroxybutynin and atomoxetine (AD109) for the treatment of obstructive sleep apnea: Rationale, design and baseline characteristics of the phase 3 clinical trials.

2025-08-171 citations

0783 Demographic and Baseline Disease Characteristics of SynAIRgy: A Phase 3 Trial of Aroxybutynin and Atomoxetine (AD109) in Obstructive Sleep Apnea

SLEEP2025-05-01

The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial.

2023-12-0147 citations